BIOMAT Database Logo BIOMAT Database Logo

Differential induction of apoptosis and senescence by the DNA methyltransferase inhibitors 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumor cells. 2013

Sascha Venturelli, and Alexander Berger, and Timo Weiland, and Frank Essmann, and Michaela Waibel, and Tina Nuebling, and Sabine Häcker, and Martin Schenk, and Klaus Schulze-Osthoff, and Helmut R Salih, and Simone Fulda, and Bence Sipos, and Ricky W Johnstone, and Ulrich M Lauer, and Michael Bitzer
Corresponding Author: Michael Bitzer, Medical University Hospital, University of Tuebingen, Otfried-Mueller-Str. 10, Tuebingen D-72076, Germany. michael.bitzer@uni-tuebingen.de.

Epigenetic alterations are a hallmark of cancer that govern the silencing of genes. Up to now, 5-azacytidine (5-aza-CR, Vidaza) and 5-aza-2'-deoxycytidine (5-aza-dC, Dacogen) are the only clinically approved DNA methyltransferase inhibitors (DNMTi). Current effort tries to exploit DNMTi application beyond acute leukemia or myelodysplastic syndrome, especially to solid tumors. Although both drugs only differ by a minimal structural difference, they trigger distinct molecular mechanisms that are highly relevant for a rational choice of new combination therapies. Therefore, we investigated cell death pathways in vitro in human hepatoma, colon, renal, and lung cancer cells and in vivo in chorioallantoic membrane and xenograft models. Real-time cancer cell monitoring and cytokine profiling revealed a profoundly distinct response pattern to both drugs. 5-aza-dC induced p53-dependent tumor cell senescence and a high number of DNA double-strand breaks. In contrast, 5-aza-CR downregulated p53, induced caspase activation and apoptosis. These individual response patterns of tumor cells could be verified in vivo in chorioallantoic membrane assays and in a hepatoma xenograft model. Although 5-aza-CR and 5-aza-dC are viewed as drugs with similar therapeutic activity, they induce a diverse molecular response in tumor cells. These findings together with other reported differences enable and facilitate a rational design of new combination strategies to further exploit the epigenetic mode of action of these two drugs in different areas of clinical oncology.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D004248 DNA (Cytosine-5-)-Methyltransferases Enzymes that catalyzes the transfer of a methyl group from S-ADENOSYLMETHIONINE to the 5-position of CYTOSINE residues in DNA. DNA (Cytosine-5-)-Methyltransferase,DNA Cytosine-5-Methylase,DNA (Cytosine 5) Methyltransferase,Cytosine-5-Methylase, DNA,DNA Cytosine 5 Methylase
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077209 Decitabine An azacitidine derivative and antineoplastic antimetabolite. It inhibits DNA methyltransferase to re-activate silent genes, limiting METASTASIS and NEOPLASM DRUG RESISTANCE. Decitabine is used in the treatment of MYELODISPLASTIC SYNDROMES, and ACUTE MYELOID LEUKEMIA. 2'-Deoxy-5-azacytidine,5-Aza-2'-deoxycytidine,5-AzadC,5-Azadeoxycytidine,5-Deoxyazacytidine,5AzadC,AzadC Compound,Dacogen,Decitabine Mesylate,NSC 127716,NSC-127716,2' Deoxy 5 azacytidine,5 Aza 2' deoxycytidine,5 Azadeoxycytidine,5 Deoxyazacytidine,Compound, AzadC,Mesylate, Decitabine,NSC127716
D001374 Azacitidine A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent. Azacytidine,5-Azacytidine,NSC-102816,Vidaza,5 Azacytidine,NSC 102816,NSC102816
D016159 Tumor Suppressor Protein p53 Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER. p53 Tumor Suppressor Protein,Cellular Tumor Antigen p53,Oncoprotein p53,TP53 Protein,TRP53 Protein,p53 Antigen,pp53 Phosphoprotein,Phosphoprotein, pp53
D016922 Cellular Senescence Process by which cells irreversibly stop dividing and enter a state of permanent growth arrest without undergoing CELL DEATH. Senescence can be induced by DNA DAMAGE or other cellular stresses, such as OXIDATIVE STRESS. Aging, Cell,Cell Aging,Cell Senescence,Replicative Senescence,Senescence, Cellular,Senescence, Replicative,Cell Ageing,Cellular Ageing,Cellular Aging,Ageing, Cell,Ageing, Cellular,Aging, Cellular,Senescence, Cell
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular

Related Publications

Sascha Venturelli, and Alexander Berger, and Timo Weiland, and Frank Essmann, and Michaela Waibel, and Tina Nuebling, and Sabine Häcker, and Martin Schenk, and Klaus Schulze-Osthoff, and Helmut R Salih, and Simone Fulda, and Bence Sipos, and Ricky W Johnstone, and Ulrich M Lauer, and Michael Bitzer
Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine.
February 1982, The Journal of biological chemistry,
Sascha Venturelli, and Alexander Berger, and Timo Weiland, and Frank Essmann, and Michaela Waibel, and Tina Nuebling, and Sabine Häcker, and Martin Schenk, and Klaus Schulze-Osthoff, and Helmut R Salih, and Simone Fulda, and Bence Sipos, and Ricky W Johnstone, and Ulrich M Lauer, and Michael Bitzer
Inhibition of shoot induction by 5-azacytidine and 5-aza-2'-deoxycytidine in Petunia involves DNA hypomethylation.
July 1997, Plant cell reports,
Sascha Venturelli, and Alexander Berger, and Timo Weiland, and Frank Essmann, and Michaela Waibel, and Tina Nuebling, and Sabine Häcker, and Martin Schenk, and Klaus Schulze-Osthoff, and Helmut R Salih, and Simone Fulda, and Bence Sipos, and Ricky W Johnstone, and Ulrich M Lauer, and Michael Bitzer
Camptothecin-induced cell proliferation inhibition and apoptosis enhanced by DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine.
June 2009, Biological & pharmaceutical bulletin,
Sascha Venturelli, and Alexander Berger, and Timo Weiland, and Frank Essmann, and Michaela Waibel, and Tina Nuebling, and Sabine Häcker, and Martin Schenk, and Klaus Schulze-Osthoff, and Helmut R Salih, and Simone Fulda, and Bence Sipos, and Ricky W Johnstone, and Ulrich M Lauer, and Michael Bitzer
Review of the clinical experience with 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumors.
April 2002, Current opinion in investigational drugs (London, England : 2000),
Sascha Venturelli, and Alexander Berger, and Timo Weiland, and Frank Essmann, and Michaela Waibel, and Tina Nuebling, and Sabine Häcker, and Martin Schenk, and Klaus Schulze-Osthoff, and Helmut R Salih, and Simone Fulda, and Bence Sipos, and Ricky W Johnstone, and Ulrich M Lauer, and Michael Bitzer
Mutagenicity of 5-aza-2'-deoxycytidine is mediated by the mammalian DNA methyltransferase.
April 1997, Proceedings of the National Academy of Sciences of the United States of America,
Sascha Venturelli, and Alexander Berger, and Timo Weiland, and Frank Essmann, and Michaela Waibel, and Tina Nuebling, and Sabine Häcker, and Martin Schenk, and Klaus Schulze-Osthoff, and Helmut R Salih, and Simone Fulda, and Bence Sipos, and Ricky W Johnstone, and Ulrich M Lauer, and Michael Bitzer
The methyltransferase inhibitor 5-aza-2-deoxycytidine induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells.
November 2005, Molecular cancer therapeutics,
Sascha Venturelli, and Alexander Berger, and Timo Weiland, and Frank Essmann, and Michaela Waibel, and Tina Nuebling, and Sabine Häcker, and Martin Schenk, and Klaus Schulze-Osthoff, and Helmut R Salih, and Simone Fulda, and Bence Sipos, and Ricky W Johnstone, and Ulrich M Lauer, and Michael Bitzer
Characteristics of mouse leukemic cells resistant to 5-azacytidine and 5-aza-2'-deoxycytidine.
October 1968, Cancer research,
Sascha Venturelli, and Alexander Berger, and Timo Weiland, and Frank Essmann, and Michaela Waibel, and Tina Nuebling, and Sabine Häcker, and Martin Schenk, and Klaus Schulze-Osthoff, and Helmut R Salih, and Simone Fulda, and Bence Sipos, and Ricky W Johnstone, and Ulrich M Lauer, and Michael Bitzer
Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine.
January 2004, Molecular pharmacology,
Sascha Venturelli, and Alexander Berger, and Timo Weiland, and Frank Essmann, and Michaela Waibel, and Tina Nuebling, and Sabine Häcker, and Martin Schenk, and Klaus Schulze-Osthoff, and Helmut R Salih, and Simone Fulda, and Bence Sipos, and Ricky W Johnstone, and Ulrich M Lauer, and Michael Bitzer
5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy.
August 2002, Oncogene,
Sascha Venturelli, and Alexander Berger, and Timo Weiland, and Frank Essmann, and Michaela Waibel, and Tina Nuebling, and Sabine Häcker, and Martin Schenk, and Klaus Schulze-Osthoff, and Helmut R Salih, and Simone Fulda, and Bence Sipos, and Ricky W Johnstone, and Ulrich M Lauer, and Michael Bitzer
Differences in DNA damage produced by incorporation of 5-aza-2'-deoxycytidine or 5,6-dihydro-5-azacytidine into DNA of mammalian cells.
November 1986, Cancer research,
Copied contents to your clipboard!